Question · asked by 1 review

Three infusions of natalizumab (300 mg) and two infusions of infliximab (5 mg/kg) vs placebo and two infusions of infliximab: Adverse events up to week 10

Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in adverse events up to week 10 compared with placebo and two infusions of infliximab (moderate certainty).

What each review found

Include earlier review versions
FindingEffectStudiesGRADE certainty
Three infusions of natalizumab (300 mg) and two infusions of infliximab (5 mg/kg) vs placebo and two infusions of infliximab
Adverse events up to week 10 · Participants with active Crohn's disease despite current treatment with infliximab
Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in adverse events up to week 10 compared with placebo and two infusions of infliximab (moderate certainty).
Natalizumab for induction of remission in Crohn's disease (2018) · Cochrane Headline outcomes only
RR 0.93 [0.85, 1.03]1 study · 79 participantsModerate

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
Natalizumab for induction of remission in Crohn's disease
2018 · Cochrane Headline outcomes only
Not reportedlist not extracted yetNot assessed

Studies behind the findings

None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.

How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.